Neurology Today in 5 - Listen - Neurology Today in 5

Listen now

More Episodes

Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies

Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game...

Published 05/02/24

ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.

Published 04/18/24

BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine

Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.

Published 04/04/24